{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:13:54Z","timestamp":1782303234192,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40121-024-01027-9","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T07:02:18Z","timestamp":1723791738000},"page":"2071-2087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States"],"prefix":"10.1007","volume":"13","author":[{"given":"Svenn Alexander","family":"Kommandantvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie H.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Zaraket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Frimpter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Helene","family":"Blanchet Zumofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"1027_CR1","unstructured":"Centers for Disease Control and Prevention. 2022\u20132023 U.S. flu season: preliminary in-season burden estimates 2023 [August 11, 2023]. Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/preliminary-in-season-estimates.htm"},{"issue":"3","key":"1027_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40273-022-01224-9","volume":"41","author":"M-H Blanchet Zumofen","year":"2023","unstructured":"Blanchet Zumofen M-H, Frimpter J, Hansen SA. Impact of influenza and influenza-like illness on work productivity outcomes: a systematic literature review. Pharmacoeconomics. 2023;41(3):253\u201373.","journal-title":"Pharmacoeconomics"},{"issue":"10095","key":"1027_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","volume":"390","author":"C Paules","year":"2017","unstructured":"Paules C, Subbarao K. Influenza. Lancet. 2017;390(10095):697\u2013708.","journal-title":"Lancet"},{"key":"1027_CR4","unstructured":"National Institute for Health and Care Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza. Technology appraisal guidance [TA168] 2009 [May 31, 2023]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta168"},{"key":"1027_CR5","unstructured":"Centers for Disease Control and Prevention. Estimated flu-related illnesses, medical visits, hospitalizations, and deaths in the United States \u2014 2018\u20132019 flu season 2020 [June 27, 2023]. Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/2018-2019.html"},{"issue":"4","key":"1027_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00011-016-0996-0","volume":"66","author":"LP Tavares","year":"2017","unstructured":"Tavares LP, Teixeira MM, Garcia CC. The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm Res. 2017;66(4):283\u2013302.","journal-title":"Inflamm Res"},{"issue":"5","key":"1027_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/irv.12470","volume":"11","author":"SA Sellers","year":"2017","unstructured":"Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372\u201393.","journal-title":"Influenza Other Respir Viruses"},{"issue":"7","key":"1027_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/aje\/kwm375","volume":"167","author":"F Carrat","year":"2008","unstructured":"Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775\u201385.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1027_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3201\/eid1201.051370","volume":"12","author":"World Health Organization Writing Group","year":"2006","unstructured":"World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12(1):81\u20137.","journal-title":"Emerg Infect Dis"},{"key":"1027_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/CEOR.S298992","volume":"13","author":"C Wallick","year":"2021","unstructured":"Wallick C, Abbass IM, Sheinson D, Moawad D. Healthcare resource use and burden associated with influenza transmission among household members with a primary infection: commercial claims data analysis. Clinicoecon Outcomes Res. 2021;13:335\u201342.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"1027_CR11","first-page":"1","volume":"60","author":"AE Fiore","year":"2011","unstructured":"Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1\u201324.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"1027_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/600383","volume":"200","author":"N Lee","year":"2009","unstructured":"Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492\u2013500.","journal-title":"J Infect Dis"},{"issue":"10","key":"1027_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"1027_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204\u201314.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1027_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1086\/650458","volume":"50","author":"S Ng","year":"2010","unstructured":"Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50(5):707\u201314.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1027_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/irv.12046","volume":"7","author":"MG Ison","year":"2013","unstructured":"Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013;7(Suppl 1):7\u201313.","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"1027_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","volume":"383","author":"H Ikematsu","year":"2020","unstructured":"Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"1027_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","volume":"12","author":"AC Hurt","year":"2012","unstructured":"Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12(3):240\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1027_CR19","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.3390\/v7092850","volume":"7","author":"TC Li","year":"2015","unstructured":"Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929\u201344.","journal-title":"Viruses"},{"key":"1027_CR20","volume-title":"US prescribing information","author":"XOFLUZA\u00ae (baloxavir marboxil)","year":"2024","unstructured":"XOFLUZA\u00ae (baloxavir marboxil). US prescribing information. South San Francisco: Genentech Inc; 2024."},{"issue":"Suppl 2","key":"1027_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.964","volume":"10","author":"JH Best","year":"2023","unstructured":"Best JH, Sadeghi MH, Sun X, et al. Household flu transmission and healthcare resource use among patients treated with baloxavir versus oseltamivir for influenza: an outpatient prospective survey in the United States. Open Forum Infect Dis. 2023;10(Suppl 2): ofad500.964.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1027_CR22","first-page":"e88","volume":"28","author":"E Neuberger","year":"2022","unstructured":"Neuberger E, Wallick C, Chawla D, Castro RC. Baloxavir vs. oseltamivir: reduced utilization and costs in influenza. Am J Manag Care. 2022;28(3):e88\u201395.","journal-title":"Am J Manag Care"},{"key":"1027_CR23","unstructured":"Data on File. F. Hoffmann-La Roche Ltd. 2023."},{"issue":"10","key":"1027_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"1027_CR25","unstructured":"Centers for Disease Control and Prevention. Flu season [July 22, 2024]. Available from: https:\/\/www.cdc.gov\/flu\/about\/season\/"},{"key":"1027_CR26","unstructured":"Centers for Disease Control and Prevention. People at higher risk of flu complications 2022 [July 13, 2023]. Available from: https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm"},{"issue":"7","key":"1027_CR27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/bcp.13229","volume":"83","author":"MA Kamal","year":"2017","unstructured":"Kamal MA, Smith PF, Chaiyakunapruk N, et al. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol. 2017;83(7):1580\u201394.","journal-title":"Br J Clin Pharmacol"},{"key":"1027_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40560-016-0178-8","volume":"4","author":"J Marti","year":"2016","unstructured":"Marti J, Hall P, Hamilton P, et al. One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. J Intensive Care. 2016;4:56.","journal-title":"J Intensive Care"},{"key":"1027_CR29","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule 2023 [July 13, 2023]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched"},{"issue":"12","key":"1027_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7326\/0000605-200912150-00156","volume":"151","author":"N Khazeni","year":"2009","unstructured":"Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med. 2009;151(12):840\u201353.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1027_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89\u2013102.","journal-title":"Med Decis Making"},{"issue":"7","key":"1027_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.vaccine.2004.12.033","volume":"24","author":"DA Turner","year":"2006","unstructured":"Turner DA, Wailoo AJ, Cooper NJ, et al. The cost-effectiveness of influenza vaccination of healthy adults 50\u201364 years of age. Vaccine. 2006;24(7):1035\u201343.","journal-title":"Vaccine"},{"issue":"4","key":"1027_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0002-9343(02)01222-6","volume":"113","author":"KJ Smith","year":"2002","unstructured":"Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113(4):300\u20137.","journal-title":"Am J Med"},{"key":"1027_CR34","volume-title":"US prescribing information","author":"TAMIFLU\u00ae (oseltamivir phosphate)","year":"2019","unstructured":"TAMIFLU\u00ae (oseltamivir phosphate). US prescribing information. South San Francisco: Genentech Inc; 2019."},{"key":"1027_CR35","unstructured":"AnalySource. AnalySource: premier access to the First Databack drug pricing database 2023 [February 2, 2024]. Available from: www.analysource.com"},{"issue":"2","key":"1027_CR36","first-page":"476","volume":"36","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Int J Epidemiol. 2006;36(2):476\u20137.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1027_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-021-01926-5","volume":"19","author":"M Yechezkel","year":"2021","unstructured":"Yechezkel M, Ndeffo Mbah ML, Yamin D. Optimizing antiviral treatment for seasonal influenza in the USA: a mathematical modeling analysis. BMC Med. 2021;19(1):54.","journal-title":"BMC Med"},{"issue":"2","key":"1027_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1017\/S0950268812000477","volume":"141","author":"KM Pepin","year":"2013","unstructured":"Pepin KM, Riley S, Grenfell BT. Effects of influenza antivirals on individual and population immunity over many epidemic waves. Epidemiol Infect. 2013;141(2):366\u201376.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"1027_CR39","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/cid\/civ084","volume":"60","author":"JJ O'Hagan","year":"2015","unstructured":"O\u2019Hagan JJ, Wong KK, Campbell AP, et al. Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic. Clin Infect Dis. 2015;60(Suppl 1):S30-41.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1027_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/cid\/ciab625","volume":"74","author":"FG Hayden","year":"2022","unstructured":"Hayden FG, Asher J, Cowling BJ, et al. Reducing influenza virus transmission: the potential value of antiviral treatment. Clin Infect Dis. 2022;74(3):532\u201340.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1027_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ajic.2007.12.003","volume":"36","author":"E Ablah","year":"2008","unstructured":"Ablah E, Konda K, Tinius A, et al. Influenza vaccine coverage and presenteeism in Sedgwick County. Kansas Am J Infect Control. 2008;36(8):588\u201391.","journal-title":"Kansas Am J Infect Control"},{"issue":"33","key":"1027_CR42","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.vaccine.2013.04.081","volume":"31","author":"S Karve","year":"2013","unstructured":"Karve S, Meier G, Davis KL, et al. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013;31(33):3370\u201388.","journal-title":"Vaccine"},{"issue":"1","key":"1027_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/irv.12696","volume":"14","author":"P Sendi","year":"2020","unstructured":"Sendi P, Drager S, Batzer B, et al. The financial burden of an influenza outbreak in a small rehabilitation centre. Influenza Other Respir Viruses. 2020;14(1):72\u20136.","journal-title":"Influenza Other Respir Viruses"},{"issue":"28","key":"1027_CR44","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1016\/j.vaccine.2012.04.057","volume":"30","author":"IR Ortega-Sanchez","year":"2012","unstructured":"Ortega-Sanchez IR, Molinari NA, Fairbrother G, et al. Indirect, out-of-pocket and medical costs from influenza-related illness in young children. Vaccine. 2012;30(28):4175\u201381.","journal-title":"Vaccine"},{"issue":"7","key":"1027_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10096-016-2641-9","volume":"35","author":"T Heikkinen","year":"2016","unstructured":"Heikkinen T, Silvennoinen H, Heinonen S, Vuorinen T. Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children. Eur J Clin Microbiol Infect Dis. 2016;35(7):1107\u201313.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"1027_CR46","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12889-020-08603-x","volume":"20","author":"S Tsuzuki","year":"2020","unstructured":"Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20(1):568.","journal-title":"BMC Public Health"},{"key":"1027_CR47","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.12688\/f1000research.9414.1","volume":"5","author":"SI Watson","year":"2016","unstructured":"Watson SI, Chen YF, Nguyen-Van-Tam JS, et al. Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. F1000 Res. 2016;5:2293.","journal-title":"F1000 Res"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01027-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01027-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01027-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:18:43Z","timestamp":1724455123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01027-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01027-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Svenn Alexander Kommandantvold: Employee and shareholder of Roche Norge AS. Shih-Chen Chang: Employee and shareholder of Genentech Inc, a member of the Roche Group. Andy Surinach: Employee of Genesis Research, which received funding for this study from Genentech Inc, a member of the Roche Group. Vince Yau: Employee and shareholder of Genentech Inc, a member of the Roche Group. Jennie H. Best: Employee and shareholder of Genentech Inc, a member of the Roche Group. Hassan Zaraket: Employee and shareholder of Roche Products Ltd. Hao Zhou: Employee and shareholder of Genentech Inc, a member of the Roche Group. Marie-Helene Blanchet Zumofen: Employee and shareholder of F. Hoffmann-La Roche, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This cost-effectiveness model was conducted based on analyses of a secondary-use database and did not recruit any human participants or involve animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}